Uncategorized

New HIV Eradication Study: The Use of a Personalized ImmuneTherapy (AGS-004) with a Reservoir Activating Agent

Argos Therapeutics Announces Plans for HIV Eradication Study  “To create AGS-004, ribonucleic acid (RNA) is isolated from HIV particles obtained from patients, and dendritic cells are generated from a single leukapheresis procedure. Selected RNAs are then used to “program” the dendritic cells with the patient-specific payload to trigger an immune response against the patient’s HIV …

New HIV Eradication Study: The Use of a Personalized ImmuneTherapy (AGS-004) with a Reservoir Activating Agent Read More »

Free 2013 Report: New HIV, HCV and TB Drugs, Diagnostics, and Vaccines in the Research Pipeline

HIV i-Base/Treatment Action Group 2013 Pipeline Reportcalls on leaders to get the best HIV, hepatitis C virus (HCV), and tuberculosis drugs, diagnostics, and vaccines to the most people as quickly as possible– Survey shows HIV pipeline healthy, HCV drug development surging,while TB research moves forward much too slowly – – Faster research, approval, and access demanded …

Free 2013 Report: New HIV, HCV and TB Drugs, Diagnostics, and Vaccines in the Research Pipeline Read More »

ResearchMatch Connects HIV Study Volunteers with Researchers

I highly encourage everyone to join our important attempt to accelerate the cure of HIV.  Research Match also helps connect patients with other diseases with private investigators. Please forward to your friends and families.  Anyone can participate. Thank you in advance for supporting this platform! Contact: Kathy Edson (615) 343-2571/ kathleen.edson@vanderbilt.edu ResearchMatch Connects HIV Study Volunteers with Researchers Nashville, TN – June 1, 2013 — ResearchMatch (RM), the country’s first nationwide, non-profit research volunteer recruitment platform for all …

ResearchMatch Connects HIV Study Volunteers with Researchers Read More »

SANGAMO BIOSCIENCES PRESENTS CLINICAL DATA DEMONSTRATING HIV RESERVOIR REDUCTION IN HIV-INFECTED SUBJECTS TREATED WITH MODIFIED IMMUNE CELLS WITH ZINC FINGER NUCLEASES

SANGAMO BIOSCIENCES PRESENTS CLINICAL DATA DEMONSTRATING HIV RESERVOIR REDUCTION IN HIV-INFECTED SUBJECTS TREATED WITH ZFP THERAPEUTIC®, SB-728-T Unprecedented Immune Reconstitution Drives HIV Viral Reservoir DepletionEncouraging Preliminary Anti-Viral HIV Data during Treatment Interruption in Ongoing SB-728-T Phase 2 Trials Richmond, California, May 15, 2013 – Sangamo BioSciences, Inc. (Nasdaq: SGMO) announced today the presentation of new …

SANGAMO BIOSCIENCES PRESENTS CLINICAL DATA DEMONSTRATING HIV RESERVOIR REDUCTION IN HIV-INFECTED SUBJECTS TREATED WITH MODIFIED IMMUNE CELLS WITH ZINC FINGER NUCLEASES Read More »

Report from CROI-2013- My Personal Picks

CROI 2013 Report Nelson Vergel I was happy to attend  CROI-2013 in Atlanta on March 3-6, 2013.  These are areas of great interest to me and in no way attempts to summarize the main findings reported at the conference.  For abstract information, refer to https://www.retroconference.org/AbstractSearch/default2.aspx?conf=22 A baby girl gets cured   The most popular media …

Report from CROI-2013- My Personal Picks Read More »

Sexual hormones in HIV-infected patients: the influence of antiretroviral therapy

AIDS: 12 April 2002 – Volume 16 – Issue 6 – pp 934-937 Research Letters Sexual hormones in HIV-infected patients: the influence of antiretroviral therapy Collazos, Julio; Martinez, Eduardo; Mayo, José; Ibarra, Sofia Free Access Article Outline Author Information Section of Infectious Diseases, Hospital de Galdakao, Vizcaya, Spain. Received: 3 August 2001; revised: 16 November …

Sexual hormones in HIV-infected patients: the influence of antiretroviral therapy Read More »

New HIV Drugs and Formulations in the Near Future (CROI 2013 Presentation)

All of the presentations in this section were great. The one on new drugs is contained in the last set of slides (blue slides at 1:22:46) https://webcasts.retroconference.org/console/player/19437?mediaType=podiumVideo For individual reports on each drug (Thanks to Natap.org): NEW HIV DRUGS at CROI Dolutegravir Treatment Response and Safety by Key Subgroups in Treatment Naive HIV Infected Individuals – (03/16/13) Dolutegravir (DTG) …

New HIV Drugs and Formulations in the Near Future (CROI 2013 Presentation) Read More »

“Functional Cure” of HIV Claimed for Baby Treated 30 Hours After Birth

NATAP https://natap.org/_______________________________________________ “Functional Cure” of HIV Claimed for Baby Treated 30 Hours After Birth 20th Conference on Retroviruses and Opportunistic Infections, March 3-6, 2013, Atlanta Mark Mascolini An HIV-infected US infant treated from 30 hour after birth had no detectable viral load, no detectable HIV DNA in blood cells, and no HIV-specific antibodies at 26 months …

“Functional Cure” of HIV Claimed for Baby Treated 30 Hours After Birth Read More »